Method for stimulating weight loss and/or for lowering triglycerides in patients

• US 7,504,435 B2
• Filed: 04/13/2005
• Issued: 03/17/2009
• Est. Priority Date: 01/31/2001
• Status: Expired due to Fees

• Current Assignee: US Department of Veterans Affairs (Government of the United States of America), Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Morkin, Eugene, Adamson, legal representative, Goldman, Steven
• Primary Examiner(s): OH, TAYLOR V
• Application Number:
  US11/104,900
• Publication Number:
  US 20080146668A1
• Time in Patent Office: 1,434 Days
• Field of Search: 562/405,472,447 514/557,568
• US Class Current: 514/557
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.

Claims

1. A method for stimulating weight loss in an overweight animal comprising administering to the animal a therapeutically effective amount of 3,5-diiodothyropropionic acid.

2. The method of claim 1, wherein 3,5-diiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation.

3. The method of claim 2, wherein said formulation further comprises a pharmaceutically acceptable carrier.

4. The method of claim 3, wherein said formulation further comprises at least one of a stabilizer, an excipient, a solubilizer, an antioxidant, a pain-alleviating agent, and an isotonic agent.

5. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered by parenteral injection.

6. The method of claim 5, wherein said 3,5-diiodothyropropionic acid is administered by parenteral intravenous injection.

7. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered orally.

8. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered directly to the pulmonary system of the animal.

9. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered transdermally.

10. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered by implantation.

11. The method of claim 1, wherein the animal comprises a human.

12. The method of claim 1, wherein the animal comprises a domesticated animal.

13. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered at a daily dosage of 0.1 to 10.0 mg/kg.

14. The method of claim 13, wherein said daily dosage is from 1.875 to 3.75 mg/kg.

15. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered together with a conventional lipid lowering therapeutic agent.

16. A method for lowering triglyceride levels of a patient, comprising administering to the patient a therapeutically effective amount of 3,5-diiodothyropropionic acid.

17. The method of claim 16, wherein the patient is an overweight patient.

18. The method of claim 16, wherein 3,5-diiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation.

19. The method of claim 16, wherein said formulation further comprises a pharmaceutically acceptable carrier.

20. The method of claim 19, wherein said formulation further comprises at least one of a stabilizer, an excipient, a solubilizer, an antioxidant, a pain-alleviating agent, and an isotonic agent.

21. The method of claim 16, wherein said 3,5-diiodothyropropionic acid is administered by parenteral injection.

22. The method of claim 21, wherein said 3,5-diiodothyropropionic acid is administered by parenteral intravenous injection.

23. The method of claim 17, wherein said 3,5-diiodothyropropionic acid is administered orally.

24. The method of claim 17, wherein said 3,5-diiodothyropropionic acid is administered directly to the pulmonary system of the patient.

25. The method of claim 17, wherein said 3,5-diiodothyropropionic acid is administered transdermally.

26. The method of claim 17, wherein said 3,5-diiodothyropropionic acid is administered by implantation.

27. The method of claim 17 wherein said 3,5-diiodothyropropionic acid is administered at a daily dosage of 0.1 to 10.0 mg/kg.

28. The method of claim 25, wherein said daily dosage is from 1.875 to 3.75 mg/kg.

29. The method of claim 17, wherein said 3,5-diiodothyropropionic acid is administered with a conventional liquid lowering therapeutic agent.